Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonraybio CoTPE:6955 +1.11%66 Debt-to-EBITDA is 0.04 as of Jun. 2026, which is 75% below its 10-year median of 0.16. GuruFocus rates TPE:6955 with a GF Score™ of 66/100 and a GF Value™ of NT$151.96 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Bonraybio Co ranks better than 96.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bonraybio Co's Debt-to-EBITDA or its related term are showing as below:
TPE:6955'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.44 Med: 0.16 Max: 0.54
Current: 0.04
During the past 6 years, the highest Debt-to-EBITDA Ratio of Bonraybio Co was 0.54. The lowest was -0.44. And the median was 0.16.
TPE:6955's Debt-to-EBITDA is ranked better than 96.39% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs TPE:6955: 0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bonraybio Co Debt-to-EBITDA Related Terms
Bonraybio Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6955 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Bonraybio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bonraybio Co (TPE:6955) has a Debt-to-EBITDA of 0.04 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonraybio Co. This is 75% below median its historical median of 0.16. According to the industry distribution chart, Bonraybio Co ranks #17 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 3.6%.
Is Bonraybio Co's Debt-to-EBITDA too high?
Bonraybio Co's current Debt-to-EBITDA of 0.04 is 75% below median its 10-year median of 0.16. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Bonraybio Co's value of 0.04 is 97.5% below this industry median. Based on the distribution chart, Bonraybio Co ranks #17 out of 471 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonraybio Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #17 out of 471 companies for Debt-to-EBITDA. This places Bonraybio Co in the top 4% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.63. Bonraybio Co's value of 0.04 is 97.5% below this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 1.63, Bonraybio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current Debt-to-EBITDA of 0.04 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonraybio Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current Debt-to-EBITDA is 0.04, which is 75% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$151.96, compared to a current price of NT$100.00 — trading 34.2% below its estimated fair value. The current Debt-to-EBITDA is 0.04, which is 75% below median its 10-year median of 0.16 and 97.5% below the Medical Devices & Instruments industry median of 1.63. Bonraybio Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current Debt-to-EBITDA is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$100.00 is trading 34.2% below its estimated GF Value™ of NT$151.96.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
Debt-to-EBITDA: 0.04 (75% below median its 10-year median of 0.16)
GF Value™: NT$151.96 vs. price of NT$100.00 (34.2% below fair value)
Industry Position: 97.5% below the Medical Devices & Instruments median (#17 of 471)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
66GF Score
Get the complete analysis for TPE:6955
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
